Cross-border M&A Motivations and Performance Evaluation in the Healthcare Industry under the RCEP Framework A Case Study of China Resources Pharmaceutical

The research utilizes case analysis techniques to examine the driving forces behind, and the effectiveness of, the international corporate mergers and acquisitions (M&A) in China Resources Pharmaceutical within the RCEP structure. Research indicates that international mergers and acquisitions markedly improved the firms expertise in market expansion, technology acquisition, resource integration, and synergy effects. Such initiatives have stimulated an increase in revenue and profits, streamlined the cost framework, and further enhanced the firms brand prominence, innovative prowess, and competitive edge in the market. Enacting RCEP presents not only prospects for China Resources Pharmaceutical but also introduces obstacles including adherence to policies, cultural assimilation, and the merging of operations. The research suggests related strategic approaches to tackle these issues and boost the firms global competitive edge and market impact.